[Retracted] The Role of Change Rates of CYFRA21-1 and CEA in Predicting Chemotherapy Efficacy for Non-Small-Cell Lung Cancer
Table 1
Efficacy and basic characteristics of NSCLC patients after chemotherapy.
Variable
DC ()
PD ()
value
Sex, (%)
1.000
Female
25 (27.2)
3 (27.3)
Male
67 (72.8)
8 (72.7)
Weight loss, (%)
0.417
Weight
80 (87.0)
8 (72.7)
Weight
12 (13.0)
3 (27.3)
Cigarette smoking, (%)
1.000
Nonsmoker
38 (41.3)
5 (45.5)
Smoker
54 (58.7)
6 (54.5)
Age, (%)
1.000
years
67 (72.8)
8 (72.7)
years
25 (27.2)
3 (27.3)
Primary tumor type by location, (%)
0.522
Central type
39 (42.4)
3 (27.3)
Peripheral type
53 (57.6)
8 (72.7)
Histological type, (%)
0.17
ADC
52 (56.5)
7 (63.6)
SCC
35 (38.0)
2 (18.2)
Large cell
5 (5.4)
2 (18.2)
ECOG PS score, (%)
0.144
73 (79.3)
6 (54.5)
19 (20.7)
5 (45.5)
Chemotherapy regimen, (%)
0.84
GP
49 (53.3)
6 (54.5)
GC
14 (15.2)
3 (27.3)
TC
7 (7.6)
0 (0.0)
AD
8 (8.7)
1 (9.1)
AC
13 (14.1)
1 (9.1)
DP
1 (1.1)
0 (0.0)
Clinical stage, (%)
0.769
IIIb/IIIc
17 (18.5)
3 (27.3)
IV
75 (81.5)
8 (72.7)
Categorical data were described as proportional number (%), and the chi-squared test or Fisher’s exact test was selected to compare the differences between the 2 groups. Abbreviations: DC = disease control; PD = progressive disease; ADC = adenocarcinoma; SCC = squamous cell carcinoma; ECOG = eastern conference oncology group; GP = gemcitabine and cisplatin; GC = gemcitabine and carboplatin; TC = paclitaxel and carboplatin; AD = pemetrexed disodium and cisplatin; AC = pemetrexed disodium and carboplatin; DP = docetaxel and cisplatin.
